Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06625177 · ClinicalTrials.gov registry record · Phase 1
A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo
A Phase 1 study of Vitiligo, sponsored by Teva Branded Pharmaceutical Products R&D.
- Active
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 13
- Study locations
NCT06625177: Active Phase 1 study of Vitiligo, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT06625177 is a Phase 1 study of Vitiligo that is active but no longer recruiting, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 38 participants, below the 1,122-participant average among 15 other Vitiligo trials with a reported enrollment target (97% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06625177, a Phase 1 study of Vitiligo, is active but no longer recruiting, sponsored by Teva Branded Pharmaceutical Products R&D.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 13
- Study locations
Study Summary
The primary objective of the trial is to evaluate the safety of TEV-53408 administered subcutaneously for the treatment of adults with vitiligo. A secondary objective is to further evaluate the safety of TEV-53408. The planned study period per participant is 84 weeks including a screening period (up to 4 weeks), a 24-week open-label treatment period, a 16-week washout period, and a 40-week follow-up period.
Conditions Studied
Interventions
- DRUG TEV-53408
Study Locations (13)
California
- Teva Investigational Site 12044 - Fremont
- Teva Investigational Site 12051 - Irvine
- Teva Investigational Site 12046 - Pasadena
Texas
- Teva Investigational Site 12045 - Dallas
- Teva Investigational Site 12057 - Webster
Arizona
- Teva Investigational Site 12043 - Scottsdale
Arkansas
- Teva Investigational Site 12052 - Hot Springs
Florida
- Teva Investigational Site 12049 - Miramar
Illinois
- Teva Investigational Site 12047 - Chicago
Kentucky
- Teva Investigational Site 12053 - Louisville
Michigan
- Teva Investigational Site 12048 - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2024-11-11 |
| Est. Completion | 2027-06-05 |
| Phase | Phase 1 |
What the registry record for NCT06625177 still lists
NCT06625177 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,122-participant average among 15 other Vitiligo trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Vitiligo appearing as the primary indexed condition, and to 1 intervention - of which TEV-53408 is the first listed.
NCT06625177 lists 13 locations in 10 states (California, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT06625177 about?
NCT06625177 is a clinical study titled "A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo". The primary objective of the trial is to evaluate the safety of TEV-53408 administered subcutaneously for the treatment of adults with vitiligo. A secondary objective is to further evaluate the safety of TEV-53408. The planned study period per participant is 84 weeks including a screening period (...
What is the current status of trial NCT06625177?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2024-11-11. Estimated completion is 2027-06-05.
What conditions does trial NCT06625177 study?
This clinical trial studies the following conditions: Vitiligo.
What interventions are being tested in trial NCT06625177?
The interventions under investigation include: TEV-53408 (DRUG).
Who is sponsoring clinical trial NCT06625177?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06625177 being conducted?
This trial has 13 study locations across Arizona, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06625177's enrollment target sits among peer trials
38 10th of 15 higher than 6 of 15 other Vitiligo trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Vitiligo trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
RECRUITING · Phase 1
-
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
RECRUITING · Phase 3
-
The Gut and Skin Microbiome in Vitiligo Disease Progression
RECRUITING
-
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
ACTIVE NOT RECRUITING
-
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
ACTIVE NOT RECRUITING · Phase 3
-
Daily Topical Rapamycin for Vitiligo
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI